1 / 9

PHARMACEUTICAL INNOVATIONS

PHARMACEUTICAL INNOVATIONS. Panel Discussion. MODERATOR Dr. Sergio Gurrieri PANELISTS Dr. Chunlin Chen Dr. Tina Huang Dr. Larry Wang Dr. Ming Guo Dr. Xifu Liu. TECH COAST ANGELS (TCA). Largest Angel Investors Organization in the US 300 Members in 5 Networks

ardice
Download Presentation

PHARMACEUTICAL INNOVATIONS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PHARMACEUTICAL INNOVATIONS Panel Discussion • MODERATOR • Dr. Sergio Gurrieri • PANELISTS • Dr. Chunlin Chen • Dr. Tina Huang • Dr. Larry Wang • Dr. Ming Guo • Dr. Xifu Liu

  2. TECH COAST ANGELS (TCA) • Largest Angel Investors Organization in the US • 300 Members in 5 Networks • Over 160 companies ($116 M) -> $1.3 B of VC Financing • Members Provide Capital as well as Knowledge & Guidance • Technology with High Barriers to Entry (IP) • Exponential Growth Potential ($50-100M) • “Pre-Money” Value $2-4M • Funding: $0.5-1.5M -> 25% of company • Exit in 4-6 yrs with 5-10x ROI • Strong & Coachable Management Team • “Angels Don’t Do Drugs” • SG -> BioMed & BioTech Inland Empire Santa Barbara Los Angeles Orange County San Diego 2 min - 2:53

  3. MAIN FOCUS • Business Models • Role of CROs in Drug Discovery R&D Innovation • Strategic Partnerships • Startups & Funding • Regulatory Challenges • FDA & SFDA Processes & Requirements • Western vs Chinese Environments • R&D and Market • Needs, Challenges & Trends • Audience Engagement SG 1 min - 3:09

  4. BUSINESS MODELS 3SBio & SK Pharma • It’s not Practical/Cost Effective for most Innovation Companies to Conduct all R&D In-House • Ascentage Pharma & 3SBio • Development & Commercialization of Best-in-Class Cancer Therapeutics Focusing on Apoptosis (Feb 12, 2010) • Medicilon & SK BioPharma • Licensing Agreement to Develop Novel Drugs for the Treatment of DEPRESSION & BIPOLAR Disorder (Oct 19, 2011) • Can you Discuss BUSINESS MODELS & the Added VALUE of These Partnerships? MG - CC 8 min - 3:17

  5. BUSINESS MODELSStrategic Partnerships • What are Other Current Partnerships • BUSINESS MODELS? • What is the STRATEGIC IMPORTANCE for Innovation Companies of Building Infrastructures in China? • What are the CHALLENGES? LW - TH - XL - AUD 23 min - 3:40

  6. BUSINESS MODELSStartups & Funding • Interest in Starting or Investing in “Virtual” Companies that Use CROs but Lack $$$ • What Kind of Business Models are most Effective Helping “Virtual” Companies Start & Grow? • What Kind of Projects might Get Funded • more Easily in China? TH - LW 10 min - 3:50

  7. REGULATORY CHALLENGES FDA vs SFDA • FDA is Increasingly Strict in Judging Efficacy of New Drugs Relative to Undesirable Side-Effects • Number of Drugs/Year Approved by the FDA is Decreasing • Is Pre-Clinical R&D Data Developed in China Acceptable for FDA Approval? • How Different Are the CHALLENGES of Running CLINICAL TRIALS in USA vs China? • What are the Major OBSTACLES for New Drugs APPROVAL? MG - XL - TH - AUD 25 min - 4:15

  8. FINAL THOUGHTSWhy is Innovation Crucial? • High & Fast Growth of R&D Capabilities in China • Substantial increase in the outsourcing of many pharmaceutical innovative pre-clinical R&D activities • Support by Chinese government -> Ownership of the Intellectual Property (IP) of newly developed drugs • Impact on Healthcare Quality • Biomarkers & Diagnostics • PharmacoGenomics & Personalized Medicine • Controlling Healthcare Costs • Alzheimer’s - $1 Trillion/year by 2050 • New Treatment -> 5 year delay -> $ 500 Billion/Year • Quality & Length of Life -> Then & Now • Polio, Cholesterol, HIV/AIDS, Leukemia, Alzheimer’s SG - ALL 4 min - 4:19

  9. THANKs to OUR PANELISTS !!! CO-FOUNDER & CEO GENERAL MANAGER Preclinical Services CO-FOUNDER & PRESIDENT CO-FOUNDER & COO CO-FOUNDER & EXECUTIVE VP, GLOBAL CLINICAL TRIALS & PRESIDENT ZENSUN USA SHANGHAI MEDICILON INC. THANK YOU SABPA !!! 1 min - 4:20

More Related